Egetis Therapeutics AB (P0F)
Market Closed
17 Jul, 20:00
€
0. 54
-0.01
-1.2844%
€
- Market Cap
- P/E Ratio
- Div Yield
1,672 Volume
- Eps
€ 0.55
Previous Close Want to track P0F and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
P0F closed yesterday lower at €0.54, a decrease of -1.2844% from Thursday's close, completing a monthly increase of 5.9055% or €0.03. Over the past 12 months, P0F stock gained 16.0734%.
P0F is not paying dividends to its shareholders.
The last earnings report, released on Apr 28, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on XSTO (SEK).
P0F Chart
Egetis Therapeutics AB (P0F) FAQ
What is the stock price today?
The current price is €0.54.
On which exchange is it traded?
Egetis Therapeutics AB is listed on XSTU.
What is its stock symbol?
The ticker symbol is P0F.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Egetis Therapeutics AB ever had a stock split?
No, there has never been a stock split.
Egetis Therapeutics AB Profile
| Biotechnology Industry | Healthcare Sector | Mr. Nicklas Westerholm CEO | XSTU Exchange | SE0003815604 ISIN |
| SE Country | 44 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Egetis Therapeutics AB (publ) is a noteworthy player in the pharmaceutical landscape, primarily concentrating on advancing projects within the late stages of development. This targeted focus is on addressing serious diseases that currently lack sufficient medical solutions, particularly within the orphan drug category. Originally established under the name PledPharma AB (publ), the company underwent a significant rebranding to Egetis Therapeutics AB (publ) in December 2020. Founded in 2006, and operating out of Stockholm, Sweden, Egetis has carved a niche for itself by tackling unmet medical needs in the healthcare sector.
Products and Services
- Aladote - Aladote represents a significant advancement in the treatment of acetaminophen/paracetamol poisoning, aimed at mitigating the risk of acute liver injury. Currently navigating the stage of phase IIb/III clinical trial, Aladote showcases Egetis Therapeutics AB’s dedication to innovating within the field of critical care medicine.
- Emcitate - Emcitate addresses a very specific and challenging medical condition known as MCT8 deficiency. This condition is characterized by its highly debilitating nature and the startling absence of available treatments. Through the development of Emcitate, Egetis Therapeutics AB is paving the way in providing hope and potential relief to patients suffering from this rare disease.
Contact Information
Address: Klara Norra Kyrkogata 26, Stockholm, Sweden, 111 22
Phone: 46 86 79 72 10
Website: https://www.egetis.com
